Food and Drug Administration today approved Adynovate, Antihemophilic
Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A.
may be successfully treated with Antihemophilic
The new treatment, called Xyntha Antihemophilic
Factor (Recombinant) Plasma/Albumin Free, is a genetically engineered version of factor VIII, a protein essential for the clotting of blood.
Thromboembolic events have been reported in vWF patients treated with Antihemophilic
Factor/von Willebrand Factor Complex replacement therapy.
Prior to her death from trauma, the previously healthy female donor received 53 units of blood components and 1 pool of antihemophilic
factor, the researchers noted.
New second-generation erythropoietins, lower dosing human insulin analogs, anti-arthritic beta interferons, albumin-free antihemophilic
factors and longer-circulating colony stimulating factors will drive growth.
Food and Drug Administration to manufacture recombinant antihemophilic
factor at its new Thousand Oaks facility.
Traditional blood bank preparations of Cryo contain high concentrations of antihemophilic
factor (plasma coagulation factor VIII) and fibrinogen, but require several days, numerous pieces of laboratory equipment, and considerable staff handling to prepare .
Smith, the plaintiff in the case, sued several manufacturers of Antihemophilic
Factor Concentrate (AFT) after he became infected with acquired immune deficiency syndrome (AIDS).
Plasma fractions--albumin, antihemophilic
agents, gamma globulins, and others--are outpacing blood components in sales growth.
About ADYNOVATE ADYNOVATE, [Antihemophilic
Factor (Recombinant), PEGylated], is a human antihemophilic
factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency) for:
Under the terms of the agreement with WFH, at least 85 percent of donated factor will be Antihemophilic
Factor VIII (Recombinant), Fc Fusion Protein for the treatment of haemophilia A, with the remainder comprised of Coagulation Factor IX (Recombinant), Fc Fusion Protein for the treatment of haemophilia B.